
Vertex and Regeneron rebound with strong drug pipelines and new product approvals boosting growth.
Vertex Pharmaceuticals is poised for growth with potential FDA approval of povetacicept for kidney disease and a strong cystic fibrosis drug franchise, alongside a $10 billion acquisition expanding its pipeline. Regeneron is thriving with Dupixent's ...


